Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Martin GS, Mannino DM, Eaton S, Moss M.The epidemiology of sepsis in the United States from 1979 through 2000.N Engl J Med 348(16), 1546-1554 (2003)

  • [2]Parrillo JE, Parker MM, Natanson C, Suffredini AF,DannerRL, Cunnion RE. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.Ann Intern Med 113(3), 227-242 (1990)

  • [3]Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, CarcilloJ, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7), 1303-1310 (2001)

  • [4]Wenzel RP. Treating sepsis. N Engl J Med 347(13), 966-967 (2002)

  • [5]Hotchkiss RS, Karl IE.The pathophysiology and treatment of sepsis.N Engl J Med 348(2), 138-150 (2003)

  • [6]Povoa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 28(3), 235-243 (2002)

  • [7]Sridharan P, Chamberlain RS. The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills? Surg Infect (Larchmt) 14(6), 489-511 (2013)

  • [8]Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 39(4), 702-710 (2011)

  • [9]Mihajlovic DM, Lendak DF, Brkic SV,Draskovic BG, Mitic GP, NovakovMikic AS.Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res 93, 92-97 (2014)

  • [10]Farias MG, de Lucena NP, Dal Bo S, de Castro SM. Neutrophil CD64 expression as an important diagnostic marker of infection and sepsis in hospital patients. J Immunol Methods 414, 65-68 (2014)

  • [11]Adly AA, Ismail EA, Andrawes NG, El-Saadany MA. Circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as diagnostic and prognostic marker in neonatal sepsis. Cytokine 65(2), 184-91 (2014)

  • [12]Biron BM, Ayala A, Lomas-Neira JL. Biomarkers for Sepsis: What Is and What Might Be? Biomark Insights10(Suppl 4), 7-17 (2015)

  • [13]Volk HD, Thieme M,Heym S, Docke WD, Ruppe U, Tausch W. Alterations in function and phenotype of monocytes from patients with septic disease--predictive value and new therapeutic strategies. Behring InstMitt(88)208-215 (1991)

  • [14]Wu JF,Ma J, Chen J,Ou-Yang B, Chen MY, Li LF. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis. Crit Care 15(5), R220 (2011)

  • [15]Lekkou A, Karakantza M, Mouzaki A, Kalfarentzos F, Gogos CA. Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections. ClinDiagn Lab Immunol 11(1), 161-167 (2004)

  • [16]Perry SE,Mostafa SM,Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 29(8), 1245-1252 (2003)

  • [17]Gogos C, Kotsaki A,Pelekanou A,Giannikopoulos G, Vaki I, Maravitsa P. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care 14(3), R96 (2010)

  • [18]Genel F, Atlihan F,Ozsu E, Ozbek E. Monocyte HLA-DR expression as predictor of poor outcome in neonates with late onset neonatal sepsis. J Infect 60(3), 224-248 (2010)

  • [19]Flohe S, Scholz M. HLA-DR monitoring in the intensive care unit--more than a tool for the scientist in the laboratory? Crit Care Med 37(10), 2849-2850 (2009)

  • [20]Landelle C,Lepape A, Voirin N,Tognet E, Venet F, Bohe J. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 36(11), 1859-1866 (2010)

  • [21]Lukaszewicz AC,Grienay M, Resche-Rigon M, Pirracchio R,Faivre V, BovalB.Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 37(10), 2746-2752 (2009)

  • [22]Gouel-Cheron A,Allaouchiche B,Floccard B,Rimmele T, Monneret G. Early daily mHLA-DR monitoring predicts forthcoming sepsis in severe trauma patients. Intensive Care Med 41(12), 2229-2230 (2015)

  • [23]Monneret G,Lepape A, Venet F.A dynamic view of mHLA-DR expression in management of severe septic patients.Crit Care15(5), 198 (2011)

  • [24]Schefold JC. Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure. Intensive Care Med 36(11), 1810-1812 (2010)

  • [25]Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 369(9), 840-851 (2013)

  • [26]Haveman JW, Muller Kobold AC, Tervaert JW, van den Berg AP, Tulleken JE, KallenbergCG. The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth J Med55(3), 132-141 (1999)

  • [27]Vincent JL, Opal SM,Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 381(9868), 774-775 (2013)

  • [28]eutschman CS, TraceyKJ. Sepsis: current dogma and new perspectives. Immunity 40(4), 463-475 (2014)

  • [29]Otto GP,Sossdorf M,Claus RA,Rodel J,Menge K,Reinhart K. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 15(4), R183 (2011)

  • [30]KalilAC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 37(8), 2350-2358 (2009)

  • [31]Boomer JS,To K, Chang KC, Takasu O, Osborne DF, Walton AH. Immunosuppression in patients who die of sepsis and multiple organ failure. Jama 306(23), 2594-2605 (2011)

  • [32]Monneret G,Venet F,Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony. Mol Med 14(1-2), 64-78 (2008)

  • [33]Ward NS,Casserly B, Ayala A.The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients.Clin Chest Med 29(4), 617-625, viii (2008)

  • [34]Hotchkiss RS, Monnere G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12), 862-874 (2013)

  • [35]Hotchkiss RS, Opal S. Immunotherapy for sepsis--a new approach against an ancient foe. N Engl J Med363(1), 87-89 (2010)

  • [36]Cheadle WG. The human leukocyte antigens and their relationship to infection. Am J Surg 165(2A Suppl), 75s-81s (1993)

  • [37]Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C. Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J RespirCrit Care Med 169(10), 1144-1151 (2004)

  • [38]Docke WD, Randow F,Syrbe U,Krausch D,Asadullah K,Reinke P. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3(6), 678-681 (1997)

  • [39]Meisel C,Schefold JC,Pschowski R,Baumann T, Hetzger K,Gregor J. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J RespirCrit Care Med 180(7), 640-648 (2009)

  • [40]Lin HY. (Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin). Zhonghua Yi XueZaZhi 87(7), 451-457 (2007)

  • [41]Schneider C,von Aulock S, Zedler S,Schinkel C, Hartung T, Faist E. Perioperative recombinant human granulocyte colony-stimulating factor (Filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 239(1), 75-81 (2004)

  • [42]Schefold JC,von Haehling S, Corsepius M, Pohle C,Kruschke P,Zuckermann H. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 28(4), 418-425 (2007)

  • [43]Hirasawa H, OdaS, Matsuda K. Continuous hemodiafiltration with cytokine-adsorbing hemofilter in the treatment of severe sepsis and septic shock. ContribNephrol 156, 365-370 (2007)

  • [44]Polk HCJr,GeorgeCD,Wellhausen SR,Cost K,Davidson PR, Regan MP. A systematic study of host defense processes in badly injured patients. Ann Surg 204(3), 282-299 (1986)

  • [45]Muller Kobold AC,Tulleken JE, Zijlstra JG,Sluiter W,Hermans J,Kallenberg CG. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med 26(7), 883-892 (2000)

  • [46]Cheron A,Floccard B, Allaouchiche B,Guignant C,Poitevin F,Malcus C. Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care 14(6), R208 (2010)

  • [47]Gouel-Cheron A,Allaouchiche B,Guignant C,Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS One 7(3), e33095 (2012)

  • [48]Pradhan R,Jain P,Paria A,Saha A,Sahoo J, Sen A. Ratio of neutrophilic CD64 and monocytic HLA-DR: A novel parameter in diagnosis and prognostication of neonatal sepsis. Cytometry B ClinCytom (2015)

  • [49]Monneret G,Lepape A,Voirin N, Bohe J,Venet F,Debard AL. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32(8), 1175-1183 (2006)

  • [50]Caille V, Chiche JD, Nciri N,Berton C,Gibot S,Boval B. Histocompatibility leukocyte antigen-D related expression is specifically altered and predicts mortality in septic shock but not in other causes of shock. Shock 22(6), 521-526 (2004)

  • [51]Demaret J,Walencik A, Jacob MC,Timsit JF,Venet F,Lepape A. Inter-laboratory assessment of flow cytometric monocyte HLA-DR expression in clinical samples. Cytometry B ClinCytom 84(1), 59-62 (2013)

  • [52]Docke WD,Hoflich C, Davis KA,Rottgers K, Meisel C,Kiefer P. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. ClinChem 51(12), 2341-2347 (2005)

  • [53]Venet F,Tissot S, Debard AL,Faudot C,Crampe C,Pachot A. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock. Crit Care Med 35(8), 1910-1917 (2007)

  • [54]Volk HD,Reinke P, Krausch D,Zuckermann H,Asadullah K, Muller JM. Monocyte deactivation--rationale for a new therapeutic strategy in sepsis. Intensive Care Med22 Suppl 4, S474-481 (1996)

  • [55]Lechner AJ,Lamprech KE,Potthoff LH,Tredway TL, Matuschak GM. Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 266(5 Pt 1), L561-568 (1994)

  • [56]Cheadle WG,Hershman MJ,Wellhausen SR, Polk HC Jr.: HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. Am J Surg 161(6), 639-645 (1991)

  • [57]Perry SE,Mostafa SM,Wenstone R, Shenkin A, McLaughlin PJ.HLA-DR regulation and the influence of GM-CSF on transcription, surface expression and shedding.Int J Med Sci 1(3), 126-136 (2004)

  • [58]Claus R,Bittorf T,Walzel H,Brock J,Uhde R,Meiske D. High concentration of soluble HLA-DR in the synovial fluid: generation and significance in “rheumatoid-like” inflammatory joint diseases. Cell Immunol 206(2), 85-100 (2000)

  • [59]Gershon HE,Kuang YD, Scala G, Oppenheim JJ.Effects of recombinant interferon-gamma on HLA-DR antigen shedding by human peripheral blood adherent mononuclear cells. J LeukocBiol 38(2), 279-291 (1985)

  • [60]Rosa F,Hatat D,Abadie A,Wallach D,Revel M, Fellous M. Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. Embo j 2(9), 1585-1589 (1983)

  • [61]FumeauxT, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J RespirCrit Care Med 166(11), 1475-1482 (2002)

  • [62]Unsinger J,Herndon JM,Davis CG,Muenzer JT,Hotchkiss RS, Ferguson TA.The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis.J Immunol 177(11), 7968-7973 (2006)

  • [63]Pinheiro-da-Silva F, Chiamolera M,Charles N, Kanamaru Y,Velasco IT, Benhamou M. B lymphocytes undergo apoptosis because of FcgammaRIIb stress response to infection: a novel mechanism of cell death in sepsis. Shock 25(1), 61-65 (2006)

  • [64]Hotchkiss RS,Osmon SB,Chang KC,Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 174(8), 5110-5118 (2005)

  • [65]Tschoeke SK, Moldawer LL. Human leukocyte antigen expression in sepsis: what have we learned? Crit Care Med 33(1), 236-237 (2005)

  • [66]Grimaldi D,Louis S, Pene F,Sirgo G,Rousseau C,Claessens YE. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med 37(9), 1438-1446 (2011)

  • [67]Poehlmann H,Schefold JC,Zuckermann-Becker H,Volk HD, Meisel C. Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a prospective observational analysis. Crit Care 13(4), R119 (2009)

  • [68]Wolk K,Docke WD,von Baehr V,Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96(1), 218-223 (2000)

  • [69]Monneret G,Finck ME, Venet F,Debard AL,Bohe J, Bienvenu J. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration. ImmunolLett 95(2), 193-198 (2004)

  • [70]Hynninen M,Pettila V,Takkunen O,Orko R,Jansson SE,Kuusela P. Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock 20(1), 1-4 (2003)

  • [71]Astiz M,Saha D,Lustbader D,Lin R, Rackow E. Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis. J Lab Clin Med 128(6), 594-600 (1996)

  • [72]Rode HN,Christou NV,Bubenik O,Superina R,Gordon J,Meakins JL.Lymphocyte function in anergic patients.ClinExpImmunol 47(1), 155-161 (1982)

  • [73]Venet F,Lukaszewicz AC,Payen D,Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. CurrOpinImmunol 25(4), 477-483 (2013)

  • [74]Hall MW,Knatz NL,Vetterly C,Tomarello S,Wewers MD,Volk HD.Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med37(3), 525-532 (2011)

  • [75]Christou NV, Meakins JL, Gordon J,Yee J,Hassan-Zahraee M,Nohr CW. The delayed hypersensitivity response and host resistance in surgical patients. 20 years later. Ann Surg 222(4), 534-546; discussion 546-548 (1995)

  • [76]MacLean LD,Meakins JL,Taguchi K, Duignan JP,Dhillon KS, Gordon J. Host resistance in sepsis and trauma. Ann Surg 182(3), 207-217 (1975)

  • [77]Venet F,Davin F,Guignant C,Larue A,Cazalis MA,Darbon R. Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 34(4), 358-363 (2010)

  • [78]Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6(11), 813-822 (2006)

  • [79]van de Veerdonk FL,Mouktaroudi M, Ramakers BP,Pistiki A,Pickkers P,van der Meer JW. Deficient Candida-specific T-helper 17 response during sepsis. J Infect Dis 206(11), 1798-1802 (2012)

  • [80]Venet F,Foray AP,Villars-Mechin A,Malcus C, Poitevin-Later F,Lepape A. IL-7 restores lymphocyte functions in septic patients. J Immunol 189(10), 5073-5081 (2012)

  • [81]Venet F,Filipe-Santos O, Lepape A,Malcus C,Poitevin-Later F, Grives A. Decreased T-cell repertoire diversity in sepsis: a preliminary study.Crit Care Med 41(1), 111-119 (2013)

  • [82]Boomer JS,Shuherk-Shaffer J,Hotchkiss RS, Green JM.A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis.Crit Care 16(3), R112 (2012)

  • [83]Guignant C,Lepape A,Huang X,Kherouf H, Denis L,Poitevin F. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 15(2), R99 (2011)

  • [84]Venet F,Chung CS,Monneret G,Huang X,Horner B,Garber M. Regulatory T cell populations in sepsis and trauma. J LeukocBiol 83(3), 523-535 (2008)

  • [85]Venet F,Lepape A, Monneret G. Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care 15(5), 231 (2011)

  • [86]Cajander S,Backman A, Tina E,Stralin K, SoderquistB, Kallman J. Preliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis. Crit Care 17(5), R223 (2013)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Mar 2017Review
Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis
Yugang Zhuang 1, Hu Peng 1, Yuanzhuo Chen 1, Shuqin Zhou 1, Yanqing Chen 1,*
Affiliation
Article Info

1 Emergency Department, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, No 301, Mid Yangchang Road, Shanghai, China

Abstract

Sepsis, an under-recognized health problem, is a major cause of death. More than 750,000 individuals develop sepsis annually, of whom 215,000 die of the disease. Clinical and experimental evidence indicates that patients with sepsis present with rapid impairment of immune function; biomarkers are therefore needed to enable early detection of this condition. Reduced monocyte human leukocyte antigen-DR (HLA-DR) expression, which is measured by flow cytometry, is currently the most popular biomarker for sepsis detection. In addition, the determination of HLA-DR expression provides valuable information in terms of predicting mortality and risk of secondary infections. HLA-DR levels have been shown to be inversely correlated with the severity of sepsis and immune dysfunction. In this review, we provide an overview of the association between sepsis and HLA-DR expression in terms of the predictive value of the latter in sepsis.

Keywords

  • Sepsis
  • Human Leukocyte Antigen DR
  • HLA-DR
  • Immunosuppression
  • Review

References